Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.66 |
| ▸ | RAB9A | P51151 | 9/20 | 0.66 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | STAT1 | P42224 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 4/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180823 | 0.83 | NPC1 (0.58) | NPC1RAB9ABIRC5SMN1; SMN2TP53 | |
| SCHEMBL15111910 | 0.82 | NPC1 (0.70) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL22661773 | 0.81 | NPC1 (0.68) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL973317 | 0.80 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2BCHEKMT2A | |
| SCHEMBL30786723 | 0.80 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2BCHEKMT2A | |
| SCHEMBL5225670 | 0.79 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL3024116 | 0.79 | BCHE (0.67) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL1464105 | 0.79 | NPC1 (1.00) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL15112605 | 0.79 | BCHE (0.68) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL28389822 | 0.79 | BCHE (0.68) | NPC1RAB9AJAK2SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458934-A | Quinoxaline compounds and uses thereof | 米伦纽姆医药公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-102656163-A | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX | 2012-09-05 | — | — | CN | disclosed |
| US-6605615-B2 | Administering to a patient suffering from hypercholesterolemia, hyperlipedimea and other metabolic disorders an effective amount of hydrozone, oxime or imine derivatives | TULARIK INC. | 2003-08-12 | — | — | US | disclosed |
| US-20010056096-A1 | Hydrazones and analogs as cholesterol lowering agents | AMGEN INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001064646-A2 | HYDRAZONES AND ANALOGS AS CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056096-A1 | Hydrazones and analogs as cholesterol lowering agents | LDLR, HDLBP, SREBF1 | NPC1 9/4885RAB9A 3049/4885BIRC5 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.